DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
Last trade$9.91
Day change-$0.36 (-3.51%)
Day range$9.75 – $10.25
Volume115,227
Market cap$645M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$645.37M
Price / earnings
—
Price / book
4.34×
Price / sales
167.85×
EV / sales
124.8×
EV / EBITDA
-2.34×
Profitability
Earnings per share
-$3.30
Return on assets
-96.25%
Return on equity
-139.43%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.24×
Quick ratio
3.24×
Cash ratio
2.83×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$191.75M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for DBVT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.6M
$700K
$900K
$645K
$2.8M
$1.5M
$800K
$511K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$1.6M
$700K
$900K
$645K
$2.8M
$1.5M
$800K
$511K
Selling, general and administrative
$19.3M
$20.1M
$15.3M
$12.8M
$8.5M
$8.9M
$5.9M
$5.47M
Research and development
$47M
$31.2M
$33.5M
$32.89M
$28.6M
$33.7M
$21.5M
$18.9M
Total operating expenses
$66.3M
$51.3M
$48.8M
$45.7M
$37.1M
$42.6M
$27.4M
$24.37M
Operating income
-$64.7M
-$50.6M
-$47.9M
-$45.05M
-$34.3M
-$41.1M
-$26.6M
-$23.86M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$64.2M
-$50.2M
-$47.4M
-$44.46M
-$33.2M
-$41.8M
-$27.1M
-$23.01M
Income taxes
$300K
$200K
$200K
$374K
$0
$100K
$0
$7K
Net income
-$64.5M
-$50.4M
-$47.6M
-$44.83M
-$33.2M
-$41.9M
-$27.1M
-$23.02M
Net income attributable to common shareholders
-$64.5M
-$50.4M
-$47.6M
-$44.83M
-$33.2M
-$41.9M
-$27.1M
-$23.02M
EBITDA
-$64.1M
-$50M
-$47M
-$44.36M
-$33.5M
-$40.4M
-$25.6M
-$23.22M
Basic earnings per share
-$0.14
-$0.12
-$0.11
-$0.24
-$0.24
-$0.31
-$0.26
-$0.23
Diluted earnings per share
-$0.14
-$0.12
-$0.11
-$0.24
-$0.24
-$0.31
-$0.26
-$0.23
Recent news
Company coverage with links to the original publishers.
DBV Technologies announced the submission of a Biologics License Application (BLA) to the FDA for its VIASKIN® Peanut patch, designed to treat peanut allergies in children aged 4-7 years. The application is based on positive results from the Phase 3 VITESSE clinical trial, the largest immunotherapy study conducted in this patient population, involving 654 children. DBV has requested priority review of the BLA.
DBV Technologies submitted a Biologics License Application (BLA) to the FDA for VIASKIN® Peanut Patch, a non-invasive epicutaneous immunotherapy treatment for peanut allergies in children aged 4-7 years. The submission is supported by positive results from the VITESSE Phase 3 clinical trial involving 654 children, the largest immunotherapy trial for this population. DBV has requested Priority Review status.
DBV Technologies announced the sale of approximately $50 million of American Depositary Shares (ADSs) through its At-The-Market (ATM) program on Nasdaq. The company had previously filed an ATM prospectus for up to $150 million in sales.
DBV Technologies announced the sale of approximately $50 million of American Depositary Shares (ADSs) through its At-The-Market (ATM) program on Nasdaq. The company had previously filed an ATM prospectus for up to $150 million in sales. As of August 31, 2026, the company had 314,388,807 total shares outstanding.
DBV Technologies announced the placement of approximately $50 million in American Depositary Shares (ADS) with RA Capital Management through its At-The-Market (ATM) program on Nasdaq. The company will issue 18.288 million new ordinary shares at $13.67 per ADS, representing a 5.82% dilution to existing shareholders. The transaction is expected to close on August 3, 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.